U.S. markets open in 4 hours 35 minutes
  • S&P Futures

    4,157.75
    +11.00 (+0.27%)
     
  • Dow Futures

    32,821.00
    +64.00 (+0.20%)
     
  • Nasdaq Futures

    13,293.00
    +64.25 (+0.49%)
     
  • Russell 2000 Futures

    1,925.50
    +3.70 (+0.19%)
     
  • Crude Oil

    88.50
    -0.51 (-0.57%)
     
  • Gold

    1,789.90
    -1.30 (-0.07%)
     
  • Silver

    20.00
    +0.16 (+0.80%)
     
  • EUR/USD

    1.0190
    +0.0002 (+0.02%)
     
  • 10-Yr Bond

    2.8400
    0.0000 (0.00%)
     
  • Vix

    21.81
    +0.37 (+1.73%)
     
  • GBP/USD

    1.2077
    +0.0007 (+0.06%)
     
  • USD/JPY

    135.1700
    +0.2000 (+0.15%)
     
  • BTC-USD

    24,085.62
    +1,104.39 (+4.81%)
     
  • CMC Crypto 200

    560.33
    +25.10 (+4.69%)
     
  • FTSE 100

    7,467.87
    +28.13 (+0.38%)
     
  • Nikkei 225

    28,249.24
    +73.37 (+0.26%)
     

Fujifilm To Buy Cell Therapy Plant From Atara For $100M

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation, will acquire a cell therapy plant from Atara Biotherapeutics Inc (NASDAQ: ATRA) for 0 million.

  • According to the company, the 90,000-square-foot facility in Thousand Oaks, California, is "readily expandable" and has the flexibility to produce clinical and commercial treatments, including allogenic T-cell and CAR-T immunotherapies.

  • As part of the deal, Fujifilm Diosynth, will begin a long-term manufacturing agreement to help produce treatments in Atara's clinical pipeline, including tabelecleucel for Epstein-Barr virus-positive lymphoproliferative disease following a transplant.

  • Also See: Atara Bio Unveils Pivotal Data On T Cell Therapy Tabelecleucel In Transplant Patients.

  • Fujifilm said it plans to offer positions to the plant's current 140 employees. "The collective expertise of the team will further support our efforts as a world-class CDMO," Fujifilm Diosynth CEO Martin Meeson said in a statement.

  • The agreement is expected to reduce Atara's planned operating expenses.

  • Upon closing, the upfront consideration, along with the reduction in operating expenses, in addition to Atara's existing cash balance, is expected to fund Atara's planned operations into Q4 2023.

  • Price Action: ATRA shares are up 4.92% at $16.00 during the premarket session on the last check Thursday.

See more from Benzinga

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.